SEARCH

SEARCH BY CITATION

References

  • 1
    Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263271.
  • 2
    Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis 1998; 61: 339342.
  • 3
    Fortune DG, Richards HL, Kirby B et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 2003; 139: 752756.
  • 4
    Finlay AY. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352353.
  • 5
    Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005; 53: S50S58.
  • 6
    Volden G, Kragballe K, van de Kerkhof PC, Aberg K, White RJ. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatolog Treat 2001; 12: 141144.
  • 7
    Seidenari S. Comparative study of the vasoconstrictor and anti-inflammatory activity (“blanching test”) of IBSA TAPE (betamethasone valerate 0.1% medicated plaster) vs. betamethasone valerate cream. Double blind, double placebo study in human volunteers. Università degli Studi di Modena e Reggio Emilia, Modena, Italy, 2001.
  • 8
    Seidenari S. Studio comparativo di IBSA TAPE (betametasone valerato cerotto), betametasone valerato e clobetasolo propionato crema, nel test di placca psoriasica. Studio in doppio cieco. Università degli Studi di Modena e Reggio Emilia, Modena, Italy, 2003.
  • 9
    Pacifico A, Daidone R, Peris K. A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 153157.
  • 10
    Naldi L, Yawalkar N, Kaszuba A et al. Efficacy and safety of the betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. Am J Clin Dermatol 2011; 12: 191201.
  • 11
    Douglas WS, Poulin Y, Decroix J et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131135.
  • 12
    Guenther L, van de Kerkhof PC, Snellman E et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316323.
  • 13
    Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389393.
  • 14
    Papp KA, Guenther L, Boyden B et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 4854.
  • 15
    Traulsen J, Hughes-Formella BJ. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology 2003; 207: 166172.
  • 16
    Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210216.
  • 17
    Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 9971035.
  • 18
    Mason J, Mason A, Cork MJ. Topical Preparations for the Treatment of Psoriasis in Primary Care: A Systematic Review. Centre for Health Services Research, University of Newcastle upon Tyne, Heslington, United Kingdom, 2002.
  • 19
    van de Kerkhof PC, Hoffmann V, Anstey A et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170176.
  • 20
    Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009: CD005028.
  • 21
    Queille-Roussel C. Evaluation of the Skin Atrophogenic Potential of IBSA TAPE (Betamethasone 0.1% Tape) Versus Betamethasone Valerate 0.12% Creams in Normal Healthy Volunteers. Centre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, France, 2002.
  • 22
    Ortonne JP. An Exploratory, Open-Label, Intra-Individual, Active-Controlled Study Comparing the Efficacy and Safety of BETESIL® Versus DAIVOBET® for the Treatment of Chronic Plaque Psoriasis. Centre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, France, 2010.